We are sorry, the page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable and you have been redirected to home page.
Molecular.roche.com
For Patients
For Labs
Screening Portfolio
Contact
  • roche logo
CERVICAL CANCER SCREENING
COBAS® HPV TEST
ATHENA HPV CLINICAL TRIAL
CLINICAL GUIDELINES
HPV NEWS & RESOURCES
Molecular.roche.com
For Patients
For Labs
Screening Portfolio
Contact

US guidance on HPV primary screening now supported by ACOG

ACOG Practice Bulletin reinforces 2015 interim guidance issued by SGO and ASCCP.                                                                                                                         

New Guidance 

A new paradigm in the fight against cervical cancer

HPV primary screening algorithm identifies more high grade disease than a Pap test alone and maintains screening efficiency.

The Case for Primary Screening 

Normal cytology doesn't always mean cancer free.

Up to one third of cervical cancers occur in screened women.1,2 Invasive cervical cancer occurs in women with normal Pap cytology.

Understand the Limitations of Pap 

  • Acronyms:

References:

1. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675-683.

2. Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.J Natl Cancer Inst. 2008;100(9):622-629.
03/12/2019

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.